BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for people who have just been diagnosed with systemic light chain (AL) amyloidosis, a condition where abnormal proteins build up in the body’s organs and tissues. The treatment being tested is called a BCMA/CD3 bispecific antibody (CM336), which is a type of medicine designed to help the immune system target and remove these harmful proteins. The goal of the study is to see how well this low-dose treatment works and to make sure it is safe for patients.

The trial is open to adults aged 65 to 74, regardless of gender, who have recently been diagnosed with this condition. If you join the study, you will receive the new treatment and be closely monitored by doctors at a single medical center. Since this is an early phase study, the focus will be on understanding how the treatment affects your health and whether there are any side effects. It’s important to know that the study is not yet recruiting participants, but it may offer a promising option for those looking for new ways to manage AL amyloidosis.

Gender

ALL

Eligibility criteria